electroCore (ECOR)
Market Price (2/26/2026): $7.27 | Market Cap: $61.4 MilSector: Health Care | Industry: Life Sciences Tools & Services
electroCore (ECOR)
Market Price (2/26/2026): $7.27Market Cap: $61.4 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Remote Patient Monitoring. | Weak multi-year price returns2Y Excs Rtn is -36% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -45% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% | ||
| Key risksECOR key risks include [1] its persistent cash burn and need for additional financing, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Targeted Therapies, and Remote Patient Monitoring. |
| Weak multi-year price returns2Y Excs Rtn is -36% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -45% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -27% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% |
| Key risksECOR key risks include [1] its persistent cash burn and need for additional financing, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong Revenue Growth and Upgraded Financial Guidance Exceeded Expectations.
electroCore provided preliminary unaudited financial guidance on January 20, 2026, projecting record full-year 2025 revenue of approximately $31.8 million to $32.0 million, representing about 26% growth over full-year 2024 revenue of $25.2 million. Additionally, the company anticipated fourth-quarter 2025 revenue to be approximately $9.0 million to $9.2 million, marking a 30% increase over the fourth quarter of 2024. This followed strong Q3 2025 results reported on November 5, 2025, with record net sales of $8.7 million, a 33% increase year-over-year, and an increase in full-year 2025 revenue guidance to between $31.5 million and $32.5 million.
2. Strategic Expansion through the Acquisition of the Quell Portfolio and Strengthening VA Channel.
The acquisition of the Quell portfolio from NeuroMetrix expanded electroCore's non-invasive bioelectronic therapies, particularly for fibromyalgia and chronic pain, leveraging existing channels within the VA and U.K. markets. Quell Fibromyalgia is noted as the sole FDA-authorized medical device for fibromyalgia symptom reduction. Furthermore, electroCore strengthened its sales channel within the U.S. Department of Veterans Affairs (VA) by securing a new five-year contract, with prescription device revenue in Q3 2025 being driven by both gammaCore and Quell sales in the VA hospital system.
Show more
Stock Movement Drivers
Fundamental Drivers
The 44.4% change in ECOR stock from 10/31/2025 to 2/25/2026 was primarily driven by a 36.2% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.04 | 7.28 | 44.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 30 | 7.7% |
| P/S Multiple | 1.5 | 2.1 | 36.2% |
| Shares Outstanding (Mil) | 8 | 8 | -1.5% |
| Cumulative Contribution | 44.4% |
Market Drivers
10/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| ECOR | 44.4% | |
| Market (SPY) | 1.6% | 30.0% |
| Sector (XLV) | 9.4% | 17.6% |
Fundamental Drivers
The 5.2% change in ECOR stock from 7/31/2025 to 2/25/2026 was primarily driven by a 12.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.92 | 7.28 | 5.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 26 | 30 | 12.8% |
| P/S Multiple | 2.2 | 2.1 | -4.9% |
| Shares Outstanding (Mil) | 8 | 8 | -1.8% |
| Cumulative Contribution | 5.2% |
Market Drivers
7/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| ECOR | 5.2% | |
| Market (SPY) | 10.0% | 31.9% |
| Sector (XLV) | 21.6% | 25.9% |
Fundamental Drivers
The -56.5% change in ECOR stock from 1/31/2025 to 2/25/2026 was primarily driven by a -64.5% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.72 | 7.28 | -56.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 30 | 27.9% |
| P/S Multiple | 5.8 | 2.1 | -64.5% |
| Shares Outstanding (Mil) | 8 | 8 | -4.2% |
| Cumulative Contribution | -56.5% |
Market Drivers
1/31/2025 to 2/25/2026| Return | Correlation | |
|---|---|---|
| ECOR | -56.5% | |
| Market (SPY) | 16.2% | 30.2% |
| Sector (XLV) | 8.9% | 27.3% |
Fundamental Drivers
The 38.6% change in ECOR stock from 1/31/2023 to 2/25/2026 was primarily driven by a 296.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2252026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.25 | 7.28 | 38.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 30 | 296.6% |
| P/S Multiple | 3.2 | 2.1 | -35.0% |
| Shares Outstanding (Mil) | 5 | 8 | -46.2% |
| Cumulative Contribution | 38.6% |
Market Drivers
1/31/2023 to 2/25/2026| Return | Correlation | |
|---|---|---|
| ECOR | 38.6% | |
| Market (SPY) | 76.9% | 16.1% |
| Sector (XLV) | 23.9% | 13.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ECOR Return | -63% | -56% | 55% | 172% | -72% | 60% | -69% |
| Peers Return | -8% | -14% | -45% | -36% | -27% | -20% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| ECOR Win Rate | 17% | 42% | 67% | 58% | 50% | 100% | |
| Peers Win Rate | 48% | 48% | 33% | 44% | 31% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ECOR Max Drawdown | -63% | -64% | -19% | -7% | -73% | 0% | |
| Peers Max Drawdown | -29% | -56% | -65% | -56% | -51% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LIVN, STIM, INSP, TIVC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/25/2026 (YTD)
How Low Can It Go
| Event | ECOR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.2% | -25.4% |
| % Gain to Breakeven | 1363.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -79.7% | -33.9% |
| % Gain to Breakeven | 393.3% | 51.3% |
| Time to Breakeven | 117 days | 148 days |
| 2018 Correction | ||
| % Loss | -93.8% | -19.8% |
| % Gain to Breakeven | 1513.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to LIVN, STIM, INSP, TIVC
In The Past
electroCore's stock fell -93.2% during the 2022 Inflation Shock from a high on 1/26/2021. A -93.2% loss requires a 1363.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About electroCore (ECOR)
AI Analysis | Feedback
- Medtronic for non-invasive nerve stimulation for headaches.
- Amgen for migraine treatment, but with a non-invasive device instead of drugs.
AI Analysis | Feedback
- gammaCore® Sapphire™: A non-invasive vagus nerve stimulator (nVNS) medical device used for the acute and preventive treatment of migraine and cluster headache, and for the acute treatment of Hemicrania Continua, Paroxysmal Hemicrania, and SUNCT/SUNA.
AI Analysis | Feedback
electroCore (ECOR) sells primarily to other companies, specifically through a network of distributors and strategic partners.
Based on its 2023 10-K filing, electroCore reported that its top three customers accounted for approximately 73% of its revenue for the year ended December 31, 2023. While electroCore generally does not publicly name its major distributors due to competitive reasons, it does highlight a strategic relationship with one such partner:
- TRxADE Health, Inc. (Symbol: MEDS) - electroCore entered into a distribution agreement with TRxADE Health's subsidiary, Bonum Health, LLC, in 2023 to promote gammaCore Sapphire through Bonum Health's telehealth platform.
The names of electroCore's other major customers, which are described generally as large specialty distributors or third-party logistics providers, are not explicitly disclosed in its public filings.
AI Analysis | Feedback
nullAI Analysis | Feedback
Daniel S. Goldberger, Chief Executive Officer
Mr. Goldberger became CEO of electroCore in October 2019. He has over 35 years of leadership and medical device experience, including serving as Executive Chairman and interim CEO of Repro Med Systems, Inc., a publicly traded developer of home and specialty infusion products. Previously, he was Director and Chief Executive Officer of Xtant Medical Holdings, Inc. from 2013 to 2017, where he led a turnaround with revenue growth from $30M to $90M and expanded the company's portfolio through acquisitions. He also served as Director and CEO of Sound Surgical Technologies from 2007 to 2013. Mr. Goldberger founded OptiScan Biomedical Corp. in 1994, serving as President until 2001. He also held positions at Glucon, Inc., OSI Systems, Ohmeda, Nellcor, and Hewlett Packard. Mr. Goldberger is also a Director of NeuroMetrix, Inc. from May 2025.
Joshua Lev, Chief Financial Officer
Mr. Lev was appointed Chief Financial Officer of electroCore in October 2024. He previously served as Chief Strategy Officer since January 2022 and joined the company in February 2020 as VP of Business Development, Strategy and Financial Planning. Mr. Lev brings over 15 years of experience in the financial services industry, including more than 10 years as an investment banker and investor focused on emerging growth companies. Prior to electroCore, he was Director of Business Development at Wellfleet Partners, Inc. from 2011, focusing on capital raises, M&A, and strategic transactions.
Peter S. Staats, MD, MBA, Chief Medical Officer
Dr. Staats is a co-founder of electroCore and has served on its board of directors. He founded and directed the Division of Pain Medicine at Johns Hopkins University for 10 years. Dr. Staats is internationally recognized for his work in developing neuromodulation strategies and implementing minimally invasive procedures for chronic pain, and his patents have contributed to the use of novel pharmacologic agents.
Manny Marques, Senior Vice President, Operations
Mr. Marques has extensive experience in manufacturing engineering, new product development, and Lean 6-Sigma manufacturing. He holds a B.S. in Mechanical Engineering Technology and an M.S. in Engineering Management from the New Jersey Institute of Technology. Mr. Marques holds two U.S. patents for cardiovascular medical devices.
Amanda Yanuklis, Chief of Staff
Ms. Yanuklis joined electroCore in 2017 and is a seasoned management consultant. Her expertise includes strategic planning and implementation, merger search and integration, and organizational design.
AI Analysis | Feedback
The key risks to electroCore's (ECOR) business include its liquidity and ongoing need for financing, high customer concentration with the U.S. Department of Veterans Affairs, and challenges within the competitive and evolving regulatory landscape of bioelectronic medicine.The most significant risk to electroCore is its **liquidity and persistent cash burn**, which necessitates the raising of additional funding to support product development and commercialization efforts. Despite having approximately $13.2 million in cash and equivalents as of September 30, 2025, the company has a widening net loss, with a GAAP net loss of $3.4 million in Q3 2025. ElectroCore is not yet cash flow positive from core operations, having used approximately $6.5 million to fund operations in the first nine months of 2025. Analysts project the company to incur a final loss in 2026 before potentially achieving profitability in 2027, requiring an aggressive growth rate. Failure to secure this additional financing could lead to severe dilution for existing shareholders or operational distress.
A second major risk is the company's **high degree of customer concentration**, particularly its reliance on the U.S. Department of Veterans Affairs (VA) channel. In Q2 2025, the VA channel constituted approximately 70% of electroCore's total revenue from its prescription device segment, primarily through its gammaCore product. This over-dependence means that any alterations in VA procurement policy, reimbursement rates, or budget allocations could instantly destabilize electroCore's financial model.
Finally, electroCore faces **external and strategic risks related to the competitive and regulatory landscape**. The bioelectronic medicine sector is highly competitive, and electroCore is engaged in federal litigation against an alleged copycat device, which introduces legal uncertainty and can deplete resources. While products like gammaCore and Truvaga have regulatory clearances, the landscape for novel medical devices is constantly evolving. New clinical data from competitors or changes in FDA requirements could negatively impact the commercial viability of electroCore's products or increase the cost of maintaining existing indications.
AI Analysis | Feedback
The increasing market penetration and expanded indications of competing non-invasive neuromodulation devices for migraine, specifically Nerivio (from Theranica). Nerivio directly competes with electroCore's gammaCore by offering a non-pharmacological, device-based solution for migraine treatment. Its recent achievements, such as expanded FDA clearances (e.g., for adolescents, and combined acute/preventive treatment in adults) and the successful securing of new dedicated CPT codes for remote electrical neuromodulation (REN), suggest a significant push towards broader adoption and improved patient access and reimbursement. This growth in a directly competing segment of non-invasive migraine devices could divert market share and limit the growth potential for electroCore's gammaCore.
AI Analysis | Feedback
electroCore (ECOR) develops and commercializes non-invasive vagus nerve stimulation (nVNS) therapies, primarily through its products gammaCore, TAC-STIM, Truvaga Plus, and the recently acquired Quell system. The addressable markets for these products are as follows:
- gammaCore for Headache Patients: The addressable market within the U.S. Department of Veterans Affairs (VA) system alone consists of approximately 800,000 headache patients.
- Quell System for Fibromyalgia Patients: The VA system includes 77,000 fibromyalgia patients, which represents an addressable market for the Quell system.
- U.S. Market for Opioid Detox and Relapse Prevention: While not explicitly tied to a specific current product, electroCore's strategic acquisitions aim to expand into this area. The U.S. market for opioid detox is estimated at $2.4 billion, and for relapse prevention, it is estimated at $3.7 billion.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for electroCore (ECOR) over the next 2-3 years:- Continued Expansion in the VA/DoD Hospital System: electroCore anticipates sustained revenue growth from its prescription devices, gammaCore and the newly acquired Quell Fibromyalgia, within the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) hospital systems. The company reported that 195 VA hospital facilities had purchased prescription gammaCore products as of September 30, 2025, an increase from 166 a year prior. Prescription device revenue, driven by both gammaCore and Quell sales in the VA system, grew 19% year-over-year in Q3 2025.
- Growth in General Wellness Products (Truvaga): The company expects significant revenue contributions from its non-prescription general wellness products, particularly the Truvaga brand. In the first quarter of 2025, Truvaga sales increased by 187% year-over-year. The health and wellness segment, primarily driven by the Truvaga platform, saw substantial growth, with revenue reaching $1.9 million in Q3 2025, marking a 121% year-on-year increase. The Truvaga division achieved record quarterly revenue of $1.7 million in Q3 2025, leading to an upward revision of the company's full-year 2025 revenue guidance.
- Successful Integration and Sales of the Quell Product Line: The acquisition of NeuroMetrix and its Quell product line is projected to broaden electroCore's market and diversify revenue streams. The Quell Fibromyalgia product has shown strong early traction within the VA hospital system, exceeding initial revenue expectations and being integrated into the VA channel ahead of schedule.
- International Market Expansion: electroCore is strategically expanding its international presence. A notable driver is a royalty-based arrangement for commercializing its technology in China, where a partner plans to navigate the CFDA process with a locally manufactured product and pay royalties on unit sales and revenue.
- Strategic Investments in Salesforce and Marketing: The company's strategic investments in expanding its salesforce and increasing marketing efforts across the U.S. are anticipated to sustain momentum and drive future revenue growth. While these investments may temporarily delay near-term profitability, they are expected to set the stage for accelerated revenue growth.
AI Analysis | Feedback
Share Issuance
- In June 2024, electroCore closed a registered direct offering and concurrent private placements, generating approximately $9.3 million in gross proceeds, with net proceeds of about $9.0 million allocated for sales and marketing, working capital, and general corporate purposes.
- Following June 30, 2021, the company completed a public offering that resulted in approximately $18.8 million in net proceeds.
- In September 2025, electroCore issued 360,737 shares of common stock to institutional and accredited investors to settle outstanding legal fees, a transaction that did not involve cash proceeds.
Inbound Investments
- Approximately $5.645 million of the June 2024 offering was provided by directors and officers of electroCore, as part of the total $9.3 million gross proceeds from the offering.
Outbound Investments
- electroCore acquired the Quell portfolio from NeuroMetrix in 2025, which includes Quell Fibromyalgia, and expects the projected results from Quell in the third and fourth quarters of 2025 to cover the full acquisition cost.
Capital Expenditures
- In the 12 months preceding November 2025, electroCore's capital expenditures were approximately $66,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| electroCore Earnings Notes | 12/16/2025 | |
| With electroCore Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ECOR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.28 |
| Mkt Cap | 0.1 |
| Rev LTM | 130 |
| Op Inc LTM | -7 |
| FCF LTM | -7 |
| FCF 3Y Avg | -7 |
| CFO LTM | -6 |
| CFO 3Y Avg | -7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.6% |
| Rev Chg 3Y Avg | 31.8% |
| Rev Chg Q | 15.9% |
| QoQ Delta Rev Chg LTM | 4.3% |
| Op Mgn LTM | -29.2% |
| Op Mgn 3Y Avg | -38.6% |
| QoQ Delta Op Mgn LTM | 1.4% |
| CFO/Rev LTM | -23.0% |
| CFO/Rev 3Y Avg | -34.9% |
| FCF/Rev LTM | -23.5% |
| FCF/Rev 3Y Avg | -37.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 2.1 |
| P/EBIT | -2.4 |
| P/E | -2.0 |
| P/CFO | -0.2 |
| Total Yield | -23.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -24.0% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -27.1% |
| 3M Rtn | -3.6% |
| 6M Rtn | -35.8% |
| 12M Rtn | -67.9% |
| 3Y Rtn | -74.5% |
| 1M Excs Rtn | -27.1% |
| 3M Excs Rtn | -2.9% |
| 6M Excs Rtn | -44.1% |
| 12M Excs Rtn | -84.3% |
| 3Y Excs Rtn | -147.4% |
Price Behavior
| Market Price | $7.28 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 06/22/2018 | |
| Distance from 52W High | -53.1% | |
| 50 Days | 200 Days | |
| DMA Price | $5.84 | $5.52 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 24.7% | 31.8% |
| 3M | 1YR | |
| Volatility | 82.6% | 92.7% |
| Downside Capture | 243.47 | 285.66 |
| Upside Capture | 465.32 | 164.64 |
| Correlation (SPY) | 35.7% | 29.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.94 | 2.85 | 2.12 | 2.42 | 1.41 | 0.82 |
| Up Beta | 3.07 | 2.62 | 2.98 | 2.00 | 0.95 | 0.54 |
| Down Beta | 1.35 | 1.39 | 0.88 | 0.48 | 1.22 | 0.81 |
| Up Capture | 1181% | 641% | 404% | 453% | 184% | 95% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 21 | 29 | 59 | 118 | 368 |
| Down Capture | 235% | 200% | 170% | 285% | 158% | 103% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 19 | 31 | 63 | 128 | 371 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ECOR | |
|---|---|---|---|---|
| ECOR | -63.0% | 92.2% | -0.65 | - |
| Sector ETF (XLV) | 8.4% | 17.3% | 0.31 | 28.8% |
| Equity (SPY) | 17.2% | 19.4% | 0.69 | 30.8% |
| Gold (GLD) | 75.4% | 25.7% | 2.16 | 4.7% |
| Commodities (DBC) | 9.7% | 16.9% | 0.38 | 7.9% |
| Real Estate (VNQ) | 7.2% | 16.6% | 0.25 | 25.6% |
| Bitcoin (BTCUSD) | -27.7% | 44.9% | -0.59 | 17.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ECOR | |
|---|---|---|---|---|
| ECOR | -31.4% | 88.3% | -0.04 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 10.2% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 16.3% |
| Gold (GLD) | 23.4% | 17.1% | 1.12 | 3.5% |
| Commodities (DBC) | 10.7% | 19.0% | 0.45 | 4.7% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.18 | 14.4% |
| Bitcoin (BTCUSD) | 5.1% | 57.1% | 0.31 | 7.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ECOR | |
|---|---|---|---|---|
| ECOR | -31.9% | 129.9% | 0.10 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 17.6% |
| Equity (SPY) | 15.5% | 17.9% | 0.75 | 17.8% |
| Gold (GLD) | 15.2% | 15.6% | 0.81 | 3.2% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 7.9% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | 13.6% |
| Bitcoin (BTCUSD) | 66.0% | 66.7% | 1.05 | 5.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/20/2026 | 10.2% | 14.5% | -10.3% |
| 11/5/2025 | 23.2% | 27.8% | 3.4% |
| 8/6/2025 | -29.1% | -25.8% | -29.4% |
| 3/12/2025 | -26.5% | -38.4% | -57.5% |
| 11/13/2024 | 1.5% | -25.8% | 1.6% |
| 8/7/2024 | -1.3% | -2.1% | -2.6% |
| 3/13/2024 | -5.6% | -1.2% | -11.0% |
| 11/8/2023 | 2.8% | 8.0% | -3.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 10 | 8 |
| # Negative | 8 | 11 | 13 |
| Median Positive | 4.3% | 6.9% | 7.2% |
| Median Negative | -5.3% | -9.4% | -29.4% |
| Max Positive | 23.2% | 157.4% | 151.0% |
| Max Negative | -29.1% | -38.4% | -57.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lev, Joshua S | Chief Financial Officer | Direct | Sell | 12052025 | 5.05 | 2,500 | 12,625 | 109,418 | Form |
| 2 | Goldberger, Daniel S | Chief Executive Officer | Direct | Buy | 12032025 | 4.84 | 1,000 | 4,840 | 1,416,015 | Form |
| 3 | Lev, Joshua S | Chief Financial Officer | Direct | Sell | 11142025 | 6.18 | 2,166 | 13,386 | 146,262 | Form |
| 4 | Errico, Thomas J | Direct | Buy | 8132025 | 4.47 | 15,000 | 67,050 | 1,257,862 | Form | |
| 5 | Goldberger, Daniel S | Chief Executive Officer | Direct | Buy | 8122025 | 4.23 | 1,000 | 4,230 | 1,233,320 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.